Category: Uncategorised

Schlieren, Switzerland, 5. May 2026 – arcoris bio, a Swiss life science research tools and in vitro diagnostics company, today announced the launch of its immunoMUSE^® kits, based on its breakthrough MUSE^® biomarker detection platform. With immunoMUSE^®, researchers can create their own multiplex immunofluorescence panels using their preferred antibodies, combining flexibility with high sensitivity and ease of use.

arcoris bio’s MUSE^® technology enables simultaneous detection of multiple biomarkers with exceptional sensitivity and simplified workflows. By supporting the detection of low-abundance targets within a single sample and enabling higher throughput, MUSE^® is well positioned to advance applications in digital pathology and translational research.

“With immunoMUSE^®, we put control over multiplex panel design directly into the hands of researchers,” said Simon Restrepo, CSO at arcoris bio. “Users can now leverage their own validated antibodies while benefiting from the sensitivity, scalability, and simplicity of the MUSE^® platform.”

arcoris bio will present immunoMUSE^® at the European Association for Cancer Research (EACR) Annual Congress 2026, taking place June 8-11 in Budapest, Hungary. Attendees are invited to visit the arcoris bio team at booth 63 to learn more and discuss with the experts how MUSE^® is shaping the future of biomarker detection.

For further information, please contact:
Beatrix Benz
+41 79 256 77 73
media@arcorisbio.com

 

About immunoMUSE^®
Compared to conventional staining approaches, immunoMUSE^® improves signal-to-noise ratios, enabling more reliable detection of low-abundance biomarkers and increasing overall assay sensitivity.

It is well-suited for a broad range of research applications, including:

• Oncology: profiling tumor microenvironments and identifying rare or low-abundance biomarkers
• Neurobiology: studying complex neuronal networks and subtle protein expression patterns
• Immunology: characterizing immune cell populations and their interactions
• Spatial biology: enabling multiplexed biomarker analysis while preserving spatial context within tissues

The portfolio includes:

• Activate & Amplify kits: providing all reagents required to prepare user antibodies for use with the MUSE^® system and perform staining
• Amplify kits: additional amplification reagents for expanded workflows

 

About arcoris bio
arcoris bio develops next-generation technologies for biomarker detection in research and diagnostics. Its flagship MUSE^® platform provides universal, programmable signal amplification to enable highly sensitive and multiplex assays that drive the future of digital pathology. The company is headquartered in Schlieren, Switzerland.

For more information, please visit: www.arcorisbio.com

Download the full press release.

Our Early Adopter Program offers researchers the opportunity to join us in evaluating and shaping a new, advanced immunofluorescence solution.

Selected participants receive early, complimentary access to the technology and collaborate directly with our development team. By sharing real-world data and feedback, participants help refine the solution, gain recognition for their work, and contribute to the advancement of next-generation research tools.

The exclusive Early Adopter Program has ended on 28.02.2026

arcoris bio raises CHF 6.3 million seed round to advance next-generation biomarker technology for digital pathology

• Round co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) and new as well as existing private investors.
• MUSE^®, arcoris bio’s nanotechnology platform for biomarker detection and signal amplification, enables simultaneous detection of multiple biomarkers with unprecedented ease and sensitivity.
• The funding will accelerate industrialization of the MUSE^® platform, expansion of strategic partnerships, and launch of new products.

Schlieren, Switzerland, 6. November 2025 – arcoris bio, a Swiss life science research tools and in vitro diagnostics company, has secured CHF 6.3 million in an oversubscribed seed financing round to advance the development and commercialization of its breakthrough MUSE® biomarker detection platform. The round was co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) and both existing and new private investors.

“Attracting two lead investors with deep industry expertise is a strong validation of our technical and business strategy. This support empowers us in our mission of transforming biomarker detection and digital pathology,” commented Simon Restrepo, Co-founder and CSO arcoris bio.

The financing will enable arcoris bio to industrialize MUSE^® and expand strategic partnerships and launch new products.

Matyas Vegh, CEO arcoris bio, added: “Securing this financing marks a major milestone for arcoris bio. In a challenging market, we are grateful for the trust our investors have placed in our vision. Their support empowers us to bring our innovations to market faster, strengthen our operations, and scale to meet growing industry demand.”

MUSE^® enables researchers to detect multiple biomarkers simultaneously with unprecedented ease and sensitivity. By allowing the measurement of several difficult-to-detect biomarkers within a single sample at higher throughput, MUSE^® is poised to play a pivotal role in the evolution of digital pathology.

Andreas Jenne, Investment Director at Ventura Ace, said: “We have been impressed by the arcoris bio team’s vision and early traction with industry partners. We believe MUSE^® represents a truly enabling technology for digital pathology.”

“arcoris bio’s MUSE^® technology fills a critical gap in the market to enable better diagnostics and applications like drug discovery or precision medicine. Its universal applicability is particularly exciting – MUSE^® acts like a molecular GPU, amplifying the capabilities of existing biomarker platforms and opening new paths for innovation,” highlighted Benedikt Klaes, Senior Investment Manager at ZEISS Ventures.

For further information, please contact:
Beatrix Benz
+41 79 256 77 73
media@arcorisbio.com

About arcoris bio
arcoris bio develops next-generation technologies for biomarker detection in research and
diagnostics. Its flagship MUSE® platform provides universal, programmable signal
amplification to enable highly sensitive and multiplex assays that drive the future of digital
pathology.
The company was founded by MUSE® inventors Simon Restrepo and Scott E. Fraser,
together with entrepreneur H. Kaspar Binz, and is headquartered in Schlieren, Switzerland.
For more information, please visit: www.arcorisbio.com

Download the full press release.